Stockscreener 앱 받기
7.98
2.84%
0.22
시간 외 거래:
7.82
-0.16
-2.01%
전일 마감가:
$7.76
열려 있는:
$7.83
하루 거래량:
856.89K
Relative Volume:
0.56
시가총액:
$658.93M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-2.5253
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
+15.15%
1개월 성능:
-1.54%
6개월 성능:
+52.00%
1년 성능:
-42.13%
1일 변동 폭
$7.54
$8.08
1주일 범위
$7.12
$8.08
52주 변동 폭
$2.68
$14.80
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
7.98 | 640.76M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-10-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-09-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know - Finviz
Buybacks Report: Can Replimune Group Inc expand its profit marginsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
How Replimune Group Inc. stock reacts to job market dataTrade Entry Report & Daily Growth Stock Investment Tips - mfd.ru
Insider Sell: Is Replimune Group Inc stock undervalued right now2025 Market Outlook & Daily Growth Stock Investment Tips - baoquankhu1.vn
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st
Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00 - MarketBeat
Piper Sandler Maintains 'Overweight' Rating for REPL, Raises PT to $14 | REPL Stock News - GuruFocus
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Replimune Secures Financial Runway Through 2027 - AD HOC NEWS
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Wedbush Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price - MarketBeat
Replimune Group (REPL) to Release Quarterly Earnings on Wednesday - MarketBeat
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - MSN
Replimune (REPL) Awaits FDA Approval for RP1 in Melanoma Treatme - GuruFocus
Replimune Group Q3 Earnings Summary & Key Takeaways - Benzinga
Replimune amends Hercules loan, strengthens funding runway - TipRanks
Earnings Summary: Replimune Group Q3 - Benzinga
Replimune Group, Inc. SEC 10-Q Report - TradingView
RP1 melanoma setback and SEC probe weigh on Replimune (NASDAQ: REPL) - Stock Titan
Earnings Breakdown: Replimune Group Q3 - Benzinga
Replimune Group Signs Loan and Security Agreement Amendment With Hercules Capital - TradingView
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Replimune Group, Inc. Enters into Third Amendment to Loan and Security Agreement with Hercules Capital, Inc - marketscreener.com
Replimune Group, Inc. (REPL): Investor Outlook Reveals 70% Potential Upside In Innovative Cancer Therapies - DirectorsTalk Interviews
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Replimune Group, Inc. (REPL) Stock Analysis: A 59% Potential Upside In Oncolytic Immunotherapy - DirectorsTalk Interviews
Replimune Group (NASDAQ:REPL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Aug Analyst Calls: Is now the right time to enter Replimune Group IncQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Replimune Group (NASDAQ:REPL) Trading Down 5.4%Should You Sell? - MarketBeat
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference - TipRanks
Replimune Group, Inc. Updates on RP1 and RP2 Programs - TradingView — Track All Markets
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-11 11:23:41 - Улправда
Replimune Group earns relative strength rating upgrade; hits key benchmark - MSN
Why Replimune Group Inc. stock remains a top recommendationNew Releases Roundup & HOKA model picks for your routine - ulpravda.ru
Why Replimune Group Inc. stock is seen as undervaluedCPI Data & Consistent Return Investment Signals - Улправда
How institutional buying supports Replimune Group Inc. stock - ulpravda.ru
Replimune Group (NASDAQ:REPL) Shares Up 10.9%Should You Buy? - MarketBeat
Will Replimune Group Inc. stock reach all time highs in 20252026 world cup usa national team qualification star players possession football winner prediction expert opinion - ulpravda.ru
Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL) - MarketBeat
HC Wainwright & Co. Upgrades Replimune Group (REPL) - MSN
Replimune Group (NASDAQ:REPL) Shares Down 6.4%What's Next? - MarketBeat
Replimune announces priority review for its melanoma treatment - MSN
Replimune Group (NASDAQ:REPL) Trading Up 4.8%Should You Buy? - MarketBeat
Replimune Group Inc (HAM:7R8) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Replimune Group Inc. stock overvalued by current metricsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
How Replimune Group Inc. stock trades during market volatility2025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Why Replimune Group Inc. stock could benefit from AI revolution2025 Fundamental Recap & Weekly Return Optimization Alerts - Улправда
Is Replimune Group Inc. stock supported by strong fundamentalsJuly 2025 Setups & Smart Swing Trading Alerts - Улправда
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dhingra Kapil | Director |
Dec 09 '25 |
Sale |
10.40 |
3,169 |
32,958 |
0 |
1.24%
0.19%
자본화:
|
볼륨(24시간):